Evelyn Reynolds, MD
Gynecologic Oncology · Rochester, MNNPI 1265465140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $714 and has fallen 93.2% since, to $49 in 2024.
Across 91 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$431
- Tesaro, Inc.$340
- AstraZeneca$309
- Merck$286
- Clovis Oncology, Inc.$101
- Eisai Inc.$71
- plus $324 from 11 others
What the payments were for
- Food & beverage$1,861100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $431 |
| Tesaro, Inc. | 13 | $340 |
| AstraZeneca | 18 | $309 |
| Merck | 18 | $286 |
| Clovis Oncology, Inc. | 5 | $101 |
| Eisai Inc. | 3 | $71 |
| Seagen Inc. | 3 | $56 |
| Tersera Therapeutics LLC | 2 | $53 |
| Fennec Pharmaceuticals, Inc. | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| Prescient Surgical | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Amgen | 1 | $14 |
| Fortovia Therapeutics, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Dysis Medical, Inc. | 1 | $13 |
How this compares
$1,861 in reported general payments places this provider in the 65th percentile of 39 gynecologic oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Rochester
- Jamie Bakkum-GamezRochester$51K
- William ClibyRochester$15K
- Carrie LangstraatRochester$6K
- Shariska HarringtonRochester$2K
- Amanika KumarRochester$2K
- Kelly BruceRochester$1K
- Clarissa Polen-DeRochester$783
- Anusha AdkoliRochester$301
- Chrystal StallworthRochester$154
- Andrea MarianiRochester$108
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.